SecBot SecBot
8-K ·Filed Nov 6, 2026

ELAN

Elanco Animal Health Inc
BULLISH
Impact 6/10
Horizonweeks Processed10d 20h ago SEC0001739104-26-000054
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The beat-and-raise quarter with accelerating price, 300 bps gross margin expansion, and leverage milestone below 3.0x signals strong operational momentum. Watch Q4 guidance for 4%-6% organic CC growth and the 2027 algorithm re-commitment for sustained mid-single digit top-line growth.

DirectionBullish
Confidencehigh
Horizonweeks

AdTab

● Neutral Named in this 8-K
Impact
Phase
Approved/Marketed
Time to market
Already launched and marketed in Europe (Spain, Portugal, Austria) since 2023-2024.
Next catalyst
None dated

What to watchAdTab is a minor regional brand extension of Elanco's lotilaner (Credelio) franchise, launched in select European markets. It faces heavy competition from established flea/tick brands (Bravecto, NexGard, Simparica) and Elanco's own Credelio line. No upcoming binary catalysts exist for this specific product; watch Elanco's broader pet health portfolio (Credelio Quattro, Zenrelia) for material drivers.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$25.74
T+0 close · Nov 6, 2026 · via day close
Latest settled
+4.04%
T+5 · $26.78
Vs SPY
+1.45%
α at T+5
Next horizon
T+20
in 20d
  1. T+0 · Nov 6 $25.74entry
  2. T+1 · 8d ago +4.27%α +1.91% · $26.84
  3. T+5 · 4d ago +4.04%α +1.45% · $26.78
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Elanco reported Q3 2026 revenue of $1.265B (+11% YoY, +9% organic constant currency) and adjusted EPS of $0.27, beating consensus of $0.20. The company raised full-year 2026 revenue guidance to $5.155B-$5.18B, adjusted EBITDA to $1.05B-$1.065B, and adjusted EPS to $1.17-$1.20, all above prior ranges. Adjusted gross margin expanded 300 bps YoY to 56.1%, and net leverage improved to 2.9x, unlocking capital allocation flexibility.

Key Financial Metrics

EPS (Adj.)
$0.27
est $0.20 · +35.0% · GAAP: $0.04
Revenue
$1.3B
est $1.2B · +4.5% · +11.0% YoY
Rating
strong beat
Guidance
$5.155B-$5.18B
raised
Gross Margin
56.9%

Key Facts

  • Q3 2026 revenue $1.265B, +11% YoY reported, +9% organic constant currency
  • Adjusted EPS $0.27 vs consensus $0.20, a 35% beat
  • Full-year 2026 revenue guidance raised to $5.155B-$5.18B (from $5.09B-$5.14B)
  • Full-year 2026 adjusted EPS guidance raised to $1.17-$1.20 (from $1.10-$1.16)
  • Adjusted gross margin 56.1%, +300 bps YoY
  • Net leverage ratio improved to 2.9x from 3.1x at Q2 2026
  • Pet Health revenue +14% YoY; Farm Animal +6% YoY
  • Price accelerated to 4% growth in Q3, exceeding expectations
  • Zenrelia and Credelio Quattro reached new market share highs in September
  • 2027 early outlook: mid-single digit organic CC revenue growth, high-single digit adjusted EBITDA growth, low-double digit adjusted EPS growth

Financial Impact

Revenue beat consensus by ~$55M (4.5%); adjusted EPS beat by $0.07 (35%); full-year guidance raised across all metrics

revenueepsebitdagross marginnet leverage

Segment Breakdown

SegmentRevenueGrowth
Pet Health$608.0M+14.0%
Farm Animal$631.0M+6.0%
Cattle$339.0M+17.0%
Poultry$201.0M-7.0%
Swine$91.0M+5.0%
Contract Manufacturing and Other$26.0M+136.0%

Risk Factors

  • Poultry revenue declined 7% YoY, a potential headwind from the farm animal segment
  • Seresto revenue negatively impacted by U.S. retailer inventory drawdown
  • Operating expenses up 12% YoY, driven by launch investments and compensation
  • Forward-looking statements on 2027 algorithm are aspirational and subject to competitive and macro risks

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001739104-26-000054
Document: elan-20261106.htm0001739104-26-000054
Document: 0001739104-26-000054-index-headers.html0001739104-26-000054
Document: 0001739104-26-000054-index.html0001739104-26-000054
Document: 0001739104-26-000054.txt0001739104-26-000054
8-K Data (Synthetic)0001739104-26-000054

Track record

19 reports on ELAN

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +15.03% at T+5 after the May 19, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $26.68 Now $26.41 −1.01% settles Feb 12
  2. Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $26.78 Now $26.41 −1.38% settles Feb 11
  3. Nov 6, 202610d ago 8-K Bullish 6/10 Viewing Entry $25.74 Now $26.41 +2.60% settles Feb 4
  4. Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $23.68 Now $26.41 +11.53% settles Feb 3
  5. Nov 3, 202613d ago 3 Neutral 1/10 Entry $25.31 Now $26.41 +4.35% settles Feb 2
  6. Oct 14, 20264w ago Institutional Cluster Bullish 4/10 Entry $23.54 Now $26.41 +12.19% settles Jan 12
  7. Sep 11, 20269w ago Press Release Neutral 1/10 Entry $23.17 Now $26.41 +13.98% settles Dec 7
  8. Aug 21, 202612w ago Insider Cluster Bullish 6/10 Entry $24.42 Now $26.41 +8.15% settles Nov 17
  9. Aug 21, 202612w ago Insider Cluster Bullish 4/10 Entry $24.42 Now $26.41 +8.15% settles Nov 17
  10. Aug 18, 202612w ago Insider Cluster Bullish 4/10 Entry $24.50 to $26.50 Now $26.41 +7.80% ▲ +8.16% +9.72% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 5h 30m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 6, 2026